XLR8 PBC Applications Open for Scale-Ready Health Tech Companies; Esteemed Mentor Lineup Announced

Phoenix, AZ – XLR8 PBC, Arizona’s premier program for scale-ready health tech companies, is now accepting applications for its latest cohort. With a no-cost, no-equity structure, XLR8 PBC provides health tech companies with unparalleled access to industry leaders, mentorship, and strategic resources. Applications for the program are open until February 19, 2025, offering founders the opportunity to engage with a world-class team of mentors and position their ventures for accelerated growth.Continue reading

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

— JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years —

— JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain —Continue reading

Clinical study explores regenerative therapy for epilepsy

Mayo Clinic is participating in the first in-human investigation of regenerative therapy for the treatment of drug-resistant epilepsy. The multicenter study will test the safety of implanting interneurons into the hippocampus in patients with the disease. Future studies are planned to investigate the potential for these cells to restore normal excitatory-inhibitory balance.Continue reading